<DOC>
	<DOCNO>NCT02962492</DOCNO>
	<brief_summary>The study investigation include evaluation acute effect single dose dapagliflozin ( 10mg ) , exenatide ( 5µg ) , combination exenatide dapagliflozin placebo insulinopenic condition long term effect basal condition 12 week treatment dapagliflozin , Exenatide extend release , combination Exenatide extend release dapagliflozin placebo ketogenesis , glucagon lipolysis .</brief_summary>
	<brief_title>An Investigation Into Effect Dapagliflozin Ketogenesis Type 1 Diabetes</brief_title>
	<detailed_description>The study investigation include evaluation acute effect single dose dapagliflozin ( 10mg ) , exenatide ( 5µg ) , combination exenatide dapagliflozin placebo insulinopenic condition long term effect basal condition 12 week treatment dapagliflozin , Exenatide extend release , combination Exenatide extend release dapagliflozin placebo ketogenesis , glucagon lipolysis . In acute effect study , qualify patient come fast research center . Review study procedure vitals perform . Insulin infusion ( pump ) stop basal blood , urine adipose tissue biopsy sample obtain . Placebos , exenatide ( 5µg ) dapagliflozin ( 10mg ) ( appropriate placebo ) combination exenatide dapagliflozin administer , accord randomize fashion , blood sample collect every 30 min 8 hour start treatment . Urine collect every hour 8 hour second adipose tissue biopsy collect 6 hour start treatment . Additional blood sample collect 1 , 2 , 4 6 8 hour mark MNC isolation . Plasma mononuclear cell ( MNC ) fraction prepare blood sample . The patient come back 24 hour mark fast blood urine collection . The long term study commence . Exenatide extend release dapagliflozin ( along appropriate placebo ) combination drug start continue 12 week accord original randomization day 0 . In long term study , dapagliflozin ( appropriate placebo ) start 5mg dose titrate 10mg/day 5 day . Fasting blood 24hr urine sample collect 1 , 4 8 week . At 12 week , 2nd acute effect test study repeat described . Measurements beta-hydroxybutyrate , acetoacetic acid , glucose , FFA glucagon , measure blood sample collect . HSL , GLP-1 , glycerol , electrolytes , serum bicarbonate , cortisol catecholamine measure 0 , 60 , 120 , 240 , 360 , 480 min 24hr follow single dose study 0 12 week visit baseline 1 , 4 8 week visit . Ketone body measure urine sample . All MNC adipose tissue sample test HSL SGLT2 expression .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Type 1 Diabetes least 1 year continuous subcutaneous insulin infusion ( CSII ; also know insulin pump ) HbA1c 710 % ( inclusive ) Ages 1865 year ( inclusive age 18 65 ) BMI 2030 kg/m2 Inability give inform consent Inability refusal comply protocol Use GLP1 Receptor Agonists last 3 month DPPIV SGLT2 inhibitor therapy last 1 month . Risk pancreatitis ( e.g. , history gallstone , alcohol abuse , hypertriglyceridemia ) History pancreatitis chronic pancreatitis Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) stroke previous 3 month . Congestive Heart Failure class III IV tachyarrhythmia . Hepatic disease : Severe hepatic insufficiency and/or significant abnormal liver function define : 1 . Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN 2 . Total bilirubin &gt; 2.0 mg/dL ( 34.2 µmol/L ) 3 . Positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen Hepatitis C virus antibody 4 . Liver function test 3 time upper limit normal Renal impairment ( e.g. , serum creatinine level ≥1.4 mg/dL woman , eGFR &lt; 60 mL/min/1.73 m2 ) history unstable rapidly progress renal disease end stage renal disease . History unexplained microscopic gross hematuria , microscopic hematuria visit 1 , confirm followup sample next scheduled visit . HIV positive History gastroparesis History medullary thyroid carcinoma MEN 2 syndrome History recur UTI Uncontrolled thyroid disease ( document normal TSH ) , Cushing 's syndrome , congenital adrenal hyperplasia hyperprolactinemia . Prior history malignant disease require chemotherapy patient prior history bladder cancer regardless treatment Alcoholism drug addiction . Hypertriglyceridemia ( &gt; 400 mg/dl ) . Any lifethreatening , noncardiac disease Uncontrolled hypertension ( BP &gt; 160/95 mm Hg ) Patients hypotension risk volume depletion due coexist condition concomitant medication , loop diuretic recently donate &gt; 500ml blood careful monitoring volume status Pregnant breastfeeding patient patient willing use two barrier method contraception study period ( unless sterilize IUD ) Use hormonal medication , antiobesity drug weight loss medication ( prescription OTC ) medication know exacerbate glucose tolerance ( isotretinoin , GnRH agonists , glucocorticoid , anabolic steroid , C19 progestins ) stop least 8 week . Use antiandrogens act peripherally reduce hirsutism 5alpha reductase inhibitor ( finesteride , spironolactone , flutamide ) stop least 4 week Presence hypersensitivity dapagliflozin SGLT2 inhibitor ( e.g . anaphylaxis , angioedema , exfoliative skin condition Known hypersensitivity contraindication use GLP1 receptor agonist ( exenatide , liraglutide ) Known hypersensitivity heparin/ IV catheter equipment . Eating disorder ( anorexia , bulimia ) gastrointestinal disorder Having history bariatric surgery Debilitating psychiatric disorder psychosis neurological condition might confound outcome variable Use investigational agent therapeutic regimen within 30 day study Participation concurrent clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>Ketogenesis</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>DKA</keyword>
	<keyword>ketone</keyword>
	<keyword>exenatide/Bydureon</keyword>
</DOC>